Search

Displaying results 1641 - 1650 of 5079 in total
  1. Drug

    Echothiophate

    go.drugbank.com/drugs/DB01057
    ApprovedInvestigational

    A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.

  2. Drug

    Potassium acetate

    go.drugbank.com/drugs/DB14498
    Approved

    Mixtures: ELETTROLITICA DI MANTENIMENTO CON GLUCOSIO FKI, ELETTROLITICA DI MANTENIMENTO CON GLUCOSIO FKI
  3. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  4. Drug

    Bemiparin

    go.drugbank.com/drugs/DB09258
    ApprovedInvestigationalWithdrawn

    These heparins have lower anti-thrombin activity than the traditional low molecular weight heparins and act mainly on factor-Xa, reducing the risk of bleeding due to selectivity for this specific clotting

    Products: HIBOR 2500 IU/0,2 ML KULLANIMA HAZIR 2 ENJEKTOR, HIBOR 2500 IU/0,2 ML KULLANIMA HAZIR 10 ENJEKTOR
  5. Drug

    Allogeneic Cardiosphere-Derived Cells

    go.drugbank.com/drugs/DB15744
    Investigational

    TNFa, IFN-y, IL-1B, and IL-15). The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function.

  6. Drug

    ISS-1018

    go.drugbank.com/drugs/DB05463
    Investigational

    ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha

  7. Drug

    Itopride

    go.drugbank.com/drugs/DB04924
    Investigational

    Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.

  8. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectabl...

  9. Drug

    Equine Botulinum Neurotoxin E Immune FAB2

    go.drugbank.com/drugs/DB13897
    Approved

    Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E. It is intravenously administered for the treat...

  10. Drug

    Equine Botulinum Neurotoxin C Immune FAB2

    go.drugbank.com/drugs/DB13898
    Approved

    Equine Botulinum Neurotoxin C Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype C. It is intravenously administered for the treat...